Home 2010 SAN ANTONIO Scientific Abstracts
2010 Scientific Abstracts PDF Print E-mail
Written by Rachelle Ramirez   

Download the entire 2010 CMSC Scientific Abstracts Book (pdf)


Cognition and Depression

P01 Cognitive Assessment in Multiple Sclerosis: A Clinical Approach (pdf)
P02 Low-Contrast and Near Visual Acuity Correlate with Cognitive Performance (pdf)
P03 Vitamin D Deficiency Correlates with Learning Tasks (pdf)
P04 A Motivational “Mercy Moment”: Story of Multiple Sclerosis (pdf)
P05 Multiple Sclerosis: Tysabri-Specific Effects on Cognitive Function (pdf)
P06 Utility of the SDMT Compared to the MMSE & a Standardized Cognitive Screen (pdf)

Disease Measurement, Mechanisms, and Treatment

P07 Oral Fingolimod (FTY720) Improves Performance of Daily Activities Compared with Intramuscular Interferon Beta-1a: Patient-Reported Indices for Multiple Sclerosis (Primus Activities) Results from the Transforms Phase 3 Trial (pdf)
P08 Maximizing the Myelinogenic Potential of Oligodendrocytes for Repair (pdf)
P09 The Nf1-Ras Signaling Pathway Regulates Oligodendrocyte Myelination (pdf)
P10 Quality Indicators for Multiple Sclerosis (pdf)
P11 Laboratory Use of CMSC Consensus Statement Standards for Oligoclonal Band Analysis (pdf)
P12 Clinical Usefulness of the Physical Functioning Measures in Ambulatory People With Multiple Sclerosis (pdf)

Psychosocial Issues

P13 Measuring Self-Efficacy in Multiple Sclerosis: A Newly Developed Scale and Short Forms (pdf)
P14 Symptoms That Predict Participation in People with Multiple Sclerosis (pdf)
P15 Teleconference-Delivered Fatigue Management: Efficacy and Effectiveness (pdf)
P16 In Sickness and in Health: When Illness Weds the Family (pdf)
P17 Benefits of Group Discussion About Intimacy and Sexuality for Women with Multiple Sclerosis (pdf)
P18 Psychometric Evaluation of the Quality of Life Scale Related to Bowel Management in People with Multiple Sclerosis (pdf)

Symptoms and Rehabilitation

P19 Effect of a Single Bout of Intermittent Versus Continuous Walking on Perceptions of Fatigue in People with Multiple Sclerosis (pdf)
P20 Validation of the Performance Scales Spasticity Subscale (pdf)
P21 “Spasticity: Take Control,” a New DVD, Presents an Educational Program for Managing Multiple Sclerosis Spasticity (pdf)
P22 Physical Activity Predicts Progression of Mobility Impairments in Multiple Sclerosis (pdf)
P23 Validity, Reliability, and Sensitivity of Three Gait Measures in Multiple Sclerosis (pdf)
P24 Effectiveness of Urinary Rehabilitation in Multiple Sclerosis Patients (pdf)


S01 Fatigue and Cognition Improve after One Year of Natalizumab Treatment (pdf)
S02 Cost Per Relapse Avoided and Budget Impact of Interferon Beta-1b(Extavia®) in Patients with Relapsing-Remitting Multiple Sclerosis (pdf)
S03 Self Reported Outcomes of Pediatric Multiple Sclerosis Patients to Adult Care (pdf)
S04 Acute Leukemia in Multiple Sclerosis Patients Treated with Mitoxantrone (pdf)
S05 Magnetization Transfer Ratio Imaging is Feasible in Multicenter MS Trials (pdf)
S06 The Role of Postpartum Intravenous Cortocosteroids in the Prevention of Relapses in Multiple Sclerosis (pdf)
S07 Sleep Disorders in Multiple Sclerosis (pdf)
S08 Distal Lower Limb Discoloration in Patients with Multiple Sclerosis (pdf)
S09 Recurrent and Multiphasic Disseminated Encephalomyelitis Case Series (pdf)
S10 Improvement in Low-Contrast Visual Acuity in MS Trials of Natalizumab (pdf)
S11 The Upper Range of Serum Ace Levels in MS (pdf)
S12 Effects of LSVT® on Voice and Respiration in Individuals with MS (pdf)
S14 Effectiveness of Balance Disorders Rehabilitation Treatments in Multiple Sclerosis Subjects: A Pilot Randomized Control Trial Assessing the Wii Balance Board Gaming System (pdf)
S15 Effectiveness of the Wii on Standing Balance in Individuals with MS (pdf)
S16 Life Coaching People with MS (pdf)
S17 The MS Cognitive Screening Battery Vs. Full Neuropsychological Evaluation: A Direct Comparision (pdf)
S18 Differences in Grey/White Matter Density and Brain Perfusion in Patients with Relapsing Neuromyelitis Optica: A Voxel-Based Study (pdf)
S19 NMO-IgG Presence in a Small Cohort of Patients with Atypical Presentation for MS (pdf)
S20 Decrease in Number of Flair/T2 Lesions After Starting Treatment with Natalizumab May Not Represent Brain Tissue Recovery. A Case Report (pdf)
S21 Agreement between MS-Related Variables in Medical Charts and Claims Data (pdf)
S22 Oral Fingolimod (FTY720) in Relapsing-Remitting Multiple Sclerosis (RRMS): Safety Findings from Transforms and Freedoms Trials (pdf)
S23 Reductions in MRI Activity in RRMS Patients Treated with Cladribine Tablets (pdf)
S24 Safety and Tolerability of Cladribine Tablets during the Clarity Study (pdf)
S25 Time Course of Injection-Site Reactions to Subcutaneous Interferon Beta-1a Or Glatiramer Acetate in the REGARD Study (pdf)
S26 The Betaseron® (Inteferon ? -1b) Pregnancy Registry (pdf)
S27 Therapy-Related Acute Leukemia in Mitoxantrone-Treated Veterans with MS (pdf)
S28 Cardiovascular Adverse Events with Mitoxantrone: Renew Study Results (pdf)
S29 Results from Two Phase 1 Clinical Studies of Pegylated Interferon Beta-1a (pdf)
S30 Development of a Comprehensive Fatigue Assessment Battery for Multiple Sclerosis (pdf)
S31 Oral Fingolimod (FTY720) Vs. Placebo in Relapsing-Remitting Multiple Sclerosis (RRMS): 2-Year Efficacy Results of the Phase III FREEDOMS Trial (pdf)
S32 Cognition in a Man with Kennedy’s Disease and a Demyelinating Disorder (pdf)
S33 Computerized Testing to Screen for Cognitive Impairment in MS (pdf)
S34 Differential Impact of Depression and Fatigue on Memory Function in MS (pdf)
S35 Brain MRI Activity and Expanded Disability Status Scale Score Progression in Multiple Sclerosis Patients Treated with Natalizumab Following Other Disease Modifying Treatments (pdf)
S36 A Combination of Robot-Assisted and Body Weight Supported Treadmill Training Improves Gait in Persons with Multiple Sclerosis (pdf)
S37 Evaluation of a Low-Cost Videoconferencing Application for a Remote Neurological Evaluation of Patients with Multiple Sclerosis (pdf)
S38 Participants’ Progress Through a Teleconference Fatigue Management Program (pdf)
S39 Thermosensitivity and Fatigue Affect Participation in Physical Activity in Individuals with Multiple Sclerosis (pdf)
S40 Outcomes From the Avonex® (Interferon Beta-1a) Pregnancy Exposure Registry (pdf)
S41 Postmarketing Utilization and Safety of Intramuscular Interferon Beta-1a (pdf)
S42 Alemtuzumab and Immune Thrombocytopenia Safety Monitoring Program in CAMMS223 (pdf)
S43 Baseline Characteristics of Patients in Phase 3 Studies of BG-12 in RRMS (pdf)
S44 Is Multi-Parity Protective in Multiple Sclerosis? (pdf)
S45 Validity of Self-Reported Expanded Disability Status Scale (EDSS) Scores (pdf)
S46 Profile of the Patient of Multiple Sclerosis – Behavioral Tendency Study (pdf)
S47 The Rehabilitation Neurofunctional and Virtual Reality in Rehabilitation (pdf)
S48 Disease Activity-Free Outcome with Cladribine Tablets During the Clarity Study (pdf)
S49 Patient Education Program for Treatment with Tysabri (pdf)
S50 Patient Perceptions of MS Support and Call Center Services: 2007–2009 (pdf)
S51 Intrathecal Baclofen Therapy (ITB): An Effective Treatment for Trigeminal Neuralgia (TN) in Multiple Sclerosis Patients Treated for Severe Spasticity (pdf)
S52 Post-Baseline Changes in Health-Related Quality of Life Among Multiple Sclerosis Patients in a Real-World Observational Outcomes Study (ROBUST) (pdf)
S53 Comparison of Medical Services in MS Patients Using First-Line Therapies (pdf)
S54 Second-Line Therapy Switching Among Multiple Sclerosis Patients (pdf)
S55 Adherence to Disease Modifying Therapies in Multiple Sclerosis (pdf)
S56 Adherence and Persistence Among Second-Line Disease-Modifying Therapies (pdf)
S57 Brain MRI Use as a Surrogate Marker in Routine Clinical Practice: A Retrospective Analysis (pdf)
S58 An Urgent Multiple Sclerosis Clinic: A New Model of Care (pdf)
S59 Developing a Wellness Program for People with Multiple Sclerosis: Desription and Initial Results (pdf)
S60 Severe Anemia Associated with Natalizumab Therapy: A Report of Two Cases (pdf)
S61 MSIS-29 Score Improvements After 1 Year of Natalizumab Treatment (pdf)
S62 Factors Contributing to the Quality of Life Among Individuals with MS (pdf)
S63 Central Auditory Processing Deficits in MS Patients (pdf)
S64 Patient Persistence on IFN Beta-1a in the Multiple Support Program (MSP) (pdf)
S65 Oral Fingolimod (FTY720) Vs Placebo in Relapsing-Remitting Multiple Sclerosis (RRMS): Baseline Data From a 2-Year Phase III Trial (Freedoms II) (pdf)
S66 Post-Baseline Changes in Work Productivity and Activity Impairment Among Multiple Sclerosis Patients in a Real-World Observational Outcomes Study (ROBUST) (pdf)
S67 ACTH: Modulation of Antigen Presenting Cell Phenotype and Function (pdf)
S68 Measuring Physical Function in MS: Extending the PROMIS Bank for AT Users (pdf)
S69 Longitudinal CD4, CD8 Counts in Multiple Sclerosis Patients on Natalizumab (pdf)
S70 Muscular and Gait Abnormalities in Patients with a First Clinically Demeyelinating Episode Suggestive of Multiple Sclerosis (pdf)
S71 Relationship Between Cognitive Performance and Clinical/MRI Variables in Early MS (pdf)
S72 Personality Traits and Adaptation to Neurological Disability in Multiple Sclerosis (pdf)
S73 Bowel Obsession Syndrome in MS Patients (pdf)
S74 TRANSFORMS—Oral Fingolimod (FTY720) Vs. Interferon Beta-1a (IFN?-1a) in Relapsing-Remitting Multiple Sclerosis (RRMS): Clinical Efficacy Results (pdf)
S75 Oral Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS): MRI Findings from TRANSFORMS and FREEDOMS Phase III Trials (pdf)
S76 Comparison of Functional Electric Stimulation (FES) Neuroprosthesis and Ankle Foot Orthosis (AFO) in Persons with Multiple Sclerosis (MS) (pdf)
S77 Early MRI Activity on IM IFN Beta-1a Predicts Disease Activity at 10 Years (pdf)
S78 Meeting the Needs of People with Primary Progressive MS (pdf)
S79 MS Next Step®: Information for People Newly Diagnosed (pdf)
S80 Impact of Oral Health in Multiple Sclerosis (MS) and Epilepsy: A Neurology Clinic Survey (pdf)
S81 MS Relapses in the Emergency Department (Data From RESUMS - Resource Utilization in MS) (pdf)
S82 Do Clinical Factors Improve Application of the MSSS to Individual Patients (pdf)
S83 Foix-Alajouanine Syndrome Mimicking Demyelinating Disease (pdf)
S84 The Utility of the EDSS in Predicting Neuropsychological Functioning in MS (pdf)
S85 Post Void Residual (PVR) Evaluation in MS Patients (pdf)
S86 Disease-Modifying Drug Therapy Initiation Patterns in Newly Diagnosed Multiple Sclerosis Patients (pdf)
S87 The Measurement of Upper Extremity Learned Nonuse in Multiple Sclerosis (pdf)
S88 Alemtuzumab Infusion in MS: Nursing Perspective on Infusion-Associated Reactions (pdf)
S89 Past Sun Exposure, Vitamin D Intake and Age at Onset Among Veterans with Multiple Sclerosis (pdf)
S90 Feelings of Guilt are Associated with Bowel and Bladder Incontinence and Lower Life Satisfaction in Patients with Multiple Sclerosis (pdf)
S91 Pathways of Change Experienced by People Aging with MS: Focus Group Study (pdf)
S92 Pericytes, A Novel New Adult Stem Cell, Ameliorates Autoimmune Encephalomyelitis (EAE) (pdf)
S93 Relapsing MS Patients Experience with Tysabri: A Phenomenological Investigation (pdf)
S94 Improvement in MS-Related Disability is Associated with Improvement in QoL (pdf)
S95 Work Absenteeism and Mobility Levels in the Narcoms Registry (pdf)
S96 MS Patients Prefer High Dose Oral Prednisone to Treat Acute Relapses (pdf)
S97 Fatigue and Depression are Independent Predictors of Naturally Occurring Changes in Physical Activity in Relapsing-Remitting Multiple Sclerosis (pdf)
S98 The Nature and Reasons for Multiple Sclerosis Therapy Changes for Patients Undergoing Antibody Testing (pdf)
S99 Injection Pain Decreases with New 0.5 ml Formulation of Glatiramer Acetate (pdf)
S100 Moderate Physical Activity is Associated with Increased Bone Density in MS (pdf)
S101 Transitioning a Patient From Research to Clinical Care; A Model for MS Trial Centers (pdf)
S102 Targeted Psychoeducational Intervention to Improve Relapse Assessment Skills in MS: A Pilot Study (pdf)
S103 Challenges in the Treatment of Mobility Loss and Walking Impairment in MS (pdf)
S104 Exploring the Potential of Nintendo Wii to Promote Exercise in Persons with MS (pdf)
S105 Short-Term and Long-Term Safety and Tolerability of IFN-?-1b in MS (pdf)
S106 National MS Nurse and Physician Extender Training Program (pdf)
S107 Evaluation of an Optimized Nursing Care Program for Patients with Relapsing–Remitting MS in Germany (pdf)
S108 Use of Natalizumab in Hispanic Patients with Relapsing Multiple Sclerosis (pdf)
S109 Smoking Negates Platform Therapy in Multiple Sclerosis (pdf)
S110 Optical Coherence Tomography Reveals Differing Severity of Damage Between Caucasians and African Americans with Demyelinating Disorders (pdf)
S111 Burn Prevention in Patients with Multiple Sclerosis (pdf)
S112 Developing Natalizumab Treatment Guidelines for Multiple Sclerosis Patients (pdf)
S113 Contribution of Structural and Functional Visual Outcomes to Work Capacity and Employment Status in Multiple Sclerosis (pdf)
S114 Dalfampridine Improves Walking in MS Patients: Pooled Data From 3 Clinical Trials (pdf)
S115 Resumption of Ambulation in a Non-Ambulatory 68 Year Old Female with MS Following Physical Therapy with Multiple Sclerosis Clinical Specialists (pdf)
S116 Comparison of General and MS-Specifi c Health Locus of Control (pdf)
S117 Quality of Life Data from NARCOMS: MS Disease-Related Factors (pdf)
S118 Barriers to Health Maintenance and Promotion in Women with Multiple Sclerosis in Nova Scotia Canada: A Questionnaire Study (pdf)
S119 Variability of Dosage in Compounded 4-Aminopyridine at 3 US Pharmacies (pdf)
S120 Prevalence of Anti-Nuclear Antibodies and Their Impact on Response to Immunomodulatory Therapy in Relapsing Remitting Multiple Sclerosis (pdf)
S121 Neuropsychological Assessment of Multiple Sclerosis Patients (pdf)
S122 Hematological Profi les in RRMS Patients Treated with Cladribine Tablets (pdf)
S123 Effects of Cladribine Tablets on Lymphocyte Subtypes in RRMS Patients (pdf)
S124 Spasticity, Mobility, and Balance in Persons with Multiple Sclerosis (pdf)
S125 Efficacy of Mycophenolate Mofetil in Multiple Sclerosis: A Retrospective Study (pdf)
S126 Patients’ Satisfaction with Natalizumab Increases over Time (pdf)
S127 African American MSIS-29 Scores Improve after 6 Natalizumab Infusions (pdf)
S128 Patterns of Spasticity Management in the MS Patient (pdf)
S129 Adherence to First-Line Immunomodulatory Drugs in Multiple Sclerosis (pdf)
S130 Impact of Treatment Adherence on Clinical and Economic Outcomes (pdf)
S131 Effects of Training and Education in Persons with Multiple Sclerosis (pdf)
S132 Patient-Perceived Severity of Stress Decreases Between Baseline and Fifth-Year Interval (pdf)
S133 Computer-Assisted Cognitive Rehabilitation for Multiple Sclerosis-Updated Findings (pdf)
S134 Beliefs About Breast Cancer Screening Among Women with Multiple Sclerosis (pdf)
S135 Quality of Life Data From NARCOMS: Differences by Socio-Demographic Factors (pdf)
S136 Durable Effi cacy of Alemtuzumab Treatment: Clinical Efficacy at Four Years (pdf)
S137 Early Onset of Effect with Cladribine Tablets in the Clarity Study (pdf)
S138 Manual Wheelchair Propulsion Pattern Use by People with Multiple Sclerosis (pdf)
S139 Vasculopathies Mimicking Multiple Sclerosis (pdf)
S140 CNS Demyelination and Anti TNF-A Therapy (pdf)
S141 Dynamic Balance Predicts Walking Speed and Endurance in Adults with Multiple Sclerosis (pdf)
S142 Accelerometry: Free-Living Measure of Ambulatory Impairments in Multiple Sclerosis (pdf)
S143 The Impact of Gait Disability on the Calibration of Accelerometer Output in Adults with Multiple Sclerosis (pdf)
S144 Observational Study of Multiple Sclerosis in the Iranian Population in Fraser Health, British Columbia (pdf)
S145 Development of a Scale to Measure Barriers to Disease-Modifying Therapy Adherence in Multiple Sclerosis (pdf)
S146 Effects of Natalizumab on Fatigue in MS: Findings from the ENER-G Study (pdf)
S147 Treatment of Multiple Sclerosis with Interferon-Beta-1a Associated with Warm Autoimmune Hemolytic Anemia (pdf)
S148 Quality Assurance/Performance Improvement by a Rehabilitation Team: Impact on MS Care (pdf)
S149 Pharmacokinetics of BG-12 Alone and with IFN?-1a or Glatiramer Acetate (pdf)
S150 Double-Blind, Placebo-Controlled, Multinational Study of AVP-923 for Pseudobulbar Affect in MS (pdf)
S151 A Randomized-Controlled Study of Low Fat Diet and Multiple Sclerosis (pdf)


W01 Effects of Vitamin D on the Differentiation of Regulatory T Cell Clones (pdf)
W02 Management of Progressed Multiple Sclerosis Through Day Programs (pdf)
W03 Exploring Strategies to Safeguard the Future of Multiple Sclerosis Clinical Research in Australia (pdf)
W04 Monthly Pulse Adrenocorticotropin Hormone Versus Methylprednisolone for Multiple Sclerosis Treatment (pdf)
W05 Phase 3 Study of Pegylated Interferon Beta-1a in Relapsing Multiple Sclerosis: Rationale and Design (pdf)
W06 Building Bridges in Multiple Sclerosis: Transitional Planning to Develop Capacity in Long-Term Care (pdf)
W07 Cognitive Screening for People with Multiple Sclerosis in Rural Areas (pdf)
W09 Surpass Study to Evaluate the Potential Benefi ts of Switching Multiple Sclerosis Therapy (pdf)
W10 Relative Efficacy of Repeat Course of Intravenous Methylprednisolone and Intramuscular Adrenocorticotropin in the Treatment of Acute Relapse of Multiple Sclerosis After Subresponse to Initial Course of Intravenous Methylprednisolone Reclaim: A Single-Center Pilot Study (pdf)
W11 Decide Rationale/Design: Daclizumab High-Yield Process Monotherapy in Relapsing-Remitting Multiple Sclerosis (pdf)
W12 Evidence-Based Patient Information and Informed Decision Making in Multiple Sclerosis (pdf)
W13 CARE-MS Extension Study: As-Needed Relapsing-Remitting Multiple Sclerosis Treatment Paradigm with Alemtuzumab (pdf)
W14 Stayingsmart: An Online Cognition Resource for People with Multiple Sclerosis, Carers, and Professionals (pdf)
W15 Evaluating the Long-Term Safety of Cladribine Tablets in Premiere, An Eight-Year Safety Registry (pdf)
W16 A Case Study of a Patient with Multiple Sclerosis Followed for Fifteen Years Using Patient-Reported Outcome Measures (pdf)
W17 Self-Efficacy Improvement in Multiple Sclerosis SIMS: Interim Results (pdf)
W18 Self-Management Interventions in People with Multiple Sclerosis (pdf)
W19 Self-Management in Neurologic Disorders: A Systematic Review of the Literature (pdf)
W20 Validating a Cognitive Rehabilitation Program for Executive Deficits in Multiple Sclerosis (pdf)
W21 Preliminary Evaluation of a Multiple Sclerosis Educational Track for Physical Therapy Students (pdf)
W22 Differences in Self-Reported and Objectively Measured Physical Activity in People with Multiple Sclerosis Versus Healthy Controls (pdf)
W23 Tool for Identifying a Patient Profi le of Drug Compliance (pdf)
W24 Electronic Autoinjector for Self-Injected Subcutaneous Interferon Beta-1a (pdf)
W25 A Stepwise Approach for the Treatment of Intention Tremor (pdf)
W26 The Use of Behavioral Medicine in the Interdisciplinary Treatment of Multiple Sclerosis Patients (pdf)
W27 Strategies for Yoga Teachers: Adaptive Mat Yoga for People Living with Multiple Sclerosis (pdf)
W28 Achieving Concordance in Multiple Sclerosis: A Workshop Program for Multiple Sclerosis Specialist Nurses (pdf)
W29 Did You Hear About the Guy—Goes by the Name of Flash—With Multiple Sclerosis? (pdf)
W30 Newly Diagnosed MS Dinner Series at Virginia Mason Medical Center (pdf)
W31 Evolution of the Multiple Sclerosis Social Work Collaborative of Washington MSSWCW (pdf)
W32 A Single-Use Autoinjector for Self-Injected Subcutaneous Interferon Beta-1a (pdf)


H01 TH1 amd TH17 Pathways Determine Opposite Results of Interferon Beta Treatment of Experimental Autoimmune Encephalomyelitis and Relapsing-Remitting Multiple Sclerosis (pdf)
H02 The Antiproliferative Gene to B1 is Involved in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis Pathogenesis (pdf)
H03 Assessing Functional Status in Pediatric Multiple Sclerosis Patients (pdf)
H04 Development of a Rasch-Based Ambulation Symptom Scare (pdf)
Last Updated on Thursday, 08 July 2010 14:16